The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The first of four planned modules at the new plant is expected to come online by summer 2026
Subscribe To Our Newsletter & Stay Updated
